Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at American Society of Clinical Oncology 2013 Annual Meeting
5/16/2013 7:03:21 AM
More...
|
Arno Therapeutics to Collaborate With Clarient, Inc. for Development of Diagnostic Test
5/10/2013 9:33:45 AM
More...
|
Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
4/8/2013 12:26:00 PM
More...
|
Arno Therapeutics Engages the Ruth Group for Investor Relations and Public Relations Counsel
3/19/2013 11:35:57 AM
More...
|
Arno Therapeutics Appoints Randy Thurman to the Board of Directors
1/31/2013 10:12:36 AM
More...
|
Arno Therapeutics Completes $14.9 Million Financing
12/19/2012 7:15:51 AM
More...
|
Arno Therapeutics Completes $12.7 Million Financing
11/27/2012 7:25:08 AM
More...
|
Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer With Onapristone
11/9/2012 11:25:05 AM
More...
|
Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe
6/8/2012 9:59:51 AM
More...
|
Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe
5/11/2012 10:33:44 AM
More...
|
|